BG106968A - Заместени арилпиразини - Google Patents

Заместени арилпиразини Download PDF

Info

Publication number
BG106968A
BG106968A BG106968A BG10696802A BG106968A BG 106968 A BG106968 A BG 106968A BG 106968 A BG106968 A BG 106968A BG 10696802 A BG10696802 A BG 10696802A BG 106968 A BG106968 A BG 106968A
Authority
BG
Bulgaria
Prior art keywords
alkyl
compound
whose name
group
ethylpropyl
Prior art date
Application number
BG106968A
Other languages
Bulgarian (bg)
English (en)
Inventor
Taeyoung Yoon
Ping Ge
Raymond Horvath
Lombaert Stephane De
Kevin Hodgetts
Dario Doller
Cunyu Zhang
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of BG106968A publication Critical patent/BG106968A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Pyridine Compounds (AREA)
BG106968A 2000-02-16 2002-07-31 Заместени арилпиразини BG106968A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18293400P 2000-02-16 2000-02-16
US20645500P 2000-05-22 2000-05-22
PCT/US2001/005264 WO2001060806A2 (en) 2000-02-16 2001-02-16 Substituted arylpyrazines

Publications (1)

Publication Number Publication Date
BG106968A true BG106968A (bg) 2003-04-30

Family

ID=26878562

Family Applications (2)

Application Number Title Priority Date Filing Date
BG106968A BG106968A (bg) 2000-02-16 2002-07-31 Заместени арилпиразини
BG110174A BG110174A (en) 2000-02-16 2002-07-31 Substituted arylpyrazines

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG110174A BG110174A (en) 2000-02-16 2002-07-31 Substituted arylpyrazines

Country Status (33)

Country Link
US (3) US6995161B2 (de)
EP (1) EP1255740B1 (de)
JP (1) JP2004500383A (de)
KR (2) KR20030031886A (de)
CN (1) CN1231473C (de)
AP (1) AP2002002620A0 (de)
AT (1) ATE307121T1 (de)
AU (1) AU783915B2 (de)
BG (2) BG106968A (de)
BR (1) BR0108363A (de)
CA (2) CA2651825A1 (de)
CR (1) CR6735A (de)
CZ (1) CZ20022739A3 (de)
DE (1) DE60114153T2 (de)
DK (1) DK1255740T3 (de)
DZ (1) DZ3293A1 (de)
EA (1) EA006938B1 (de)
EE (1) EE200200453A (de)
ES (1) ES2247070T3 (de)
HR (1) HRP20020747A2 (de)
HU (1) HUP0301573A3 (de)
IL (1) IL151020A0 (de)
IS (1) IS2192B (de)
MA (1) MA26874A1 (de)
MX (1) MXPA02007868A (de)
NO (1) NO324473B1 (de)
NZ (1) NZ520484A (de)
OA (1) OA12178A (de)
PL (1) PL365238A1 (de)
SK (1) SK11542002A3 (de)
TW (1) TWI232215B (de)
WO (1) WO2001060806A2 (de)
YU (1) YU61002A (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1330452T3 (da) 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
KR20040015716A (ko) 2001-05-22 2004-02-19 뉴로젠 코포레이션 Ｃｒｆ1 조절자로서의 5-치환된-2-아릴피리딘
IL159058A0 (en) * 2001-06-12 2004-05-12 Neurogen Corp 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
AU2002343557A1 (en) * 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
JP2005533014A (ja) 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004018437A1 (en) * 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
JP2006506350A (ja) * 2002-09-12 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換１，４−ピラジン誘導体
EP1565454A1 (de) * 2002-11-21 2005-08-24 Pharmacia & Upjohn Company LLC Pyrazine verbindungen als crf modulatoren
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
GEP20084341B (en) 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
EP1625125A1 (de) * 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Verbindungen als crf1 rezeptor antagonisten
MXPA05012081A (es) 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Derivados de pirimidina sustituidos.
WO2005007644A1 (ja) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
EP1678160A1 (de) * 2003-10-27 2006-07-12 Astellas Pharma Inc. Pyrazinderivate und deren pharmazeutische verwendung
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
EP1871762A2 (de) * 2005-04-18 2008-01-02 Neurogen Corporation Substituierte heteroaryle als cb1-antagonisten
DK1959955T3 (da) * 2005-12-05 2011-02-07 Pfizer Prod Inc Fremgangsmåde til behandling af abnorm cellevækst
RU2387650C2 (ru) * 2005-12-05 2010-04-27 Пфайзер Продактс Инк. Полиморфы с-met/hgfr ингибитора
SG157264A1 (en) * 2008-06-02 2009-12-29 Inzign Pte Ltd A golf tee and method of producing a golf tee
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
GEAP201814266A (en) 2014-02-14 2018-05-10 Takeda Pharmaceuticals Co Pyrazines modulators of gpr6
CA2970011C (en) 2014-12-24 2021-08-03 Lg Chem, Ltd. Biaryl derivative as gpr120 agonist
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
RU2672470C1 (ru) * 2017-07-10 2018-11-15 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Способ получения 2,3,5,6-тетрафенил(бензил)пиразина
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
MX2020011050A (es) * 2018-04-20 2021-03-09 Virginia Tech Intellectual Properties Inc Imidazopiridinas útiles como desacopladores mitocondriales.
CA3141404A1 (en) * 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
GB202006076D0 (en) * 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425355A1 (de) 1974-05-25 1975-12-04 Basf Ag Verfahren zur herstellung von pyrazinen
EG12387A (en) * 1975-04-21 1978-12-31 Merck & Co Inc Process for preparing of piperazinyl pyrazines
FR2398738A1 (fr) * 1977-06-22 1979-02-23 Lilly Co Eli Preparation de benzoylurees
US4293552A (en) * 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US4211870A (en) * 1979-04-06 1980-07-08 Eli Lilly And Company Preparation of substituted 2-aminopyrazines
JPS59144772A (ja) * 1983-02-08 1984-08-18 Ube Ind Ltd 液晶性ピラジン誘導体およびその製法
JPS625970A (ja) * 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
JPH0739398B2 (ja) * 1986-10-04 1995-05-01 宇部興産株式会社 液晶性ピラジン誘導体
NZ227684A (en) * 1988-01-30 1991-07-26 Merck Sharp & Dohme Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
JPH0348666A (ja) 1989-07-17 1991-03-01 Rasa Kogyo Kk 芳香族ジアミン化合物の製造方法
DE3940477A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Hetaryl-substituierte pyridinylpyrimidin-derivate
GB2272216A (en) * 1992-11-04 1994-05-11 Merck Patent Gmbh Liquid crystalline di-, tri- and tetra-fluorinated phenylpyrazines
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
WO1997011943A1 (en) * 1995-09-26 1997-04-03 Nippon Soda Co., Ltd. Pyrazole compounds, process for preparing the same, and agrohorticultural bactericide
ATE213495T1 (de) 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
BE1011077A3 (fr) 1997-03-28 1999-04-06 Univ Catholique Louvain Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes.
EP1052238A4 (de) 1998-01-28 2007-05-02 Shionogi & Co Neue trizyklische verbindung
GB9818881D0 (en) * 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
JP2002536320A (ja) 1999-02-02 2002-10-29 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント プテリジン誘導体の免疫抑制作用

Also Published As

Publication number Publication date
US20030018035A1 (en) 2003-01-23
ES2247070T3 (es) 2006-03-01
BG110174A (en) 2009-05-29
DK1255740T3 (da) 2006-02-06
MXPA02007868A (es) 2003-02-10
US7202250B2 (en) 2007-04-10
DE60114153T2 (de) 2006-07-06
CZ20022739A3 (cs) 2003-02-12
NO20023869D0 (no) 2002-08-15
EP1255740B1 (de) 2005-10-19
AU3849401A (en) 2001-08-27
HUP0301573A3 (en) 2004-03-29
BR0108363A (pt) 2004-02-10
NO20023869L (no) 2002-09-11
NZ520484A (en) 2005-03-24
IL151020A0 (en) 2003-02-12
TWI232215B (en) 2005-05-11
AP2002002620A0 (en) 2002-09-30
KR20080021603A (ko) 2008-03-07
IS6488A (is) 2002-07-29
OA12178A (en) 2003-12-24
CR6735A (es) 2003-11-25
NO324473B1 (no) 2007-10-29
MA26874A1 (fr) 2004-12-20
CN1400970A (zh) 2003-03-05
US20070225287A1 (en) 2007-09-27
YU61002A (sh) 2005-06-10
KR20030031886A (ko) 2003-04-23
HRP20020747A2 (en) 2004-12-31
PL365238A1 (en) 2004-12-27
US20050215559A1 (en) 2005-09-29
HUP0301573A2 (hu) 2003-12-29
EP1255740A2 (de) 2002-11-13
CA2398937A1 (en) 2001-08-23
EA200200766A1 (ru) 2003-10-30
SK11542002A3 (sk) 2003-03-04
WO2001060806A3 (en) 2002-02-07
EA006938B1 (ru) 2006-06-30
IS2192B (is) 2007-01-15
CA2651825A1 (en) 2001-08-23
AU783915B2 (en) 2005-12-22
DE60114153D1 (de) 2006-03-02
EE200200453A (et) 2003-12-15
HK1051191A1 (en) 2003-07-25
ATE307121T1 (de) 2005-11-15
CN1231473C (zh) 2005-12-14
JP2004500383A (ja) 2004-01-08
US6995161B2 (en) 2006-02-07
WO2001060806A2 (en) 2001-08-23
DZ3293A1 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
BG106968A (bg) Заместени арилпиразини
RS61002B1 (sr) Formulacija rnk za imunoterapiju
US6887875B2 (en) 2,5-diarypyrimidine compounds
BG108490A (bg) 5-заместени-2-арилпиридини като модулатори на crf1
US6943173B2 (en) 5-substituted 2-aryl-4-pyrimidinones
US7179807B2 (en) 5-substituted-2-arylpyrazines
EP1233949A2 (de) In 5-stellung substituierte arylpyrimidine
EP1500653A1 (de) Substituierte Arylpyrazine
AU2002310117A1 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as CRF1 receptor modulators